PulseDIA is a patented technique owned by Westlake Omics. This technology divides a DIA window into several windows with narrower ranges of m/zs and evenly allocates them to various spectrometric methods for acquisition. The one sample would be divided into multiple short gradient groups before entering the system. Each group generates its unique spectrometric windows, the data of which are then combined and analyzed altogether, resulting in more identifications of peptides.
Application Scenarios: Suitable for clinical cohort studies with the need for the highest depth proteomics analysis.
1. Pulse DIA improves the number of protein identifications by 10% – 30% on the basis of conventional DIA;
2. Combined with PCT sample pre-processing technology, high depth protein quantitative analysis of clinical micro samples (such as FFPE, puncture biopsy, tears, etc.) can be achieved, and the minimum sample size of tissue samples is only 0.1mg.
Bruker timsTOF Pro
Thermo Orbitrap Exploris 480
1.Cai, et al. PulseDIA: Data-Independent Acquisition Mass Spectrometry Using Multi-Injection Pulsed Gas-Phase Fractionation. Journal of Proteome Research. 2021.20(1):279-288.
2.Liu, et al. DIA-based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia. Mol Cell Prot. available at bioRxiv, 2021.